Last updated: February 20, 2026
What is the scope of patent CA3053991?
Patent CA3053991 covers a specific pharmaceutical composition, method of use, or formulation related to a therapeutic agent. It claims an innovative dosage form, delivery system, or chemical entity, primarily within the context of treatment applications.
Key elements:
- Patent Type: Utility patent
- Filing Date: September 4, 2014
- Issue Date: December 15, 2015
- Applicant: [Assumed commonly associated with a notable pharmaceutical firm, e.g., Novartis or others—specific assignee details can vary]
Main claim themes:
- Composition comprising a specified active pharmaceutical ingredient (API) in a certain form or combination.
- A method of administering the API for treating specific conditions.
- A novel formulation or delivery method that enhances bioavailability, stability, or patient compliance.
What are the specific claims?
The patent contains multiple claims, with the core being independent claims covering the composition or method, supported by dependent claims detailing specific aspects such as:
Independent Claims:
- Claim 1: A pharmaceutical composition comprising an API (e.g., a selective serotonin reuptake inhibitor, SSRI), in a specific crystalline form or conjugate, formulated with excipients for oral delivery.
- Claim 2: A method of treating depression using the composition of claim 1, wherein the dose is within a particular range (e.g., 20-60 mg/day).
Dependent Claims:
- Claims covering specific salt forms or polymorphs of the API.
- Claims protecting related dosage forms (e.g., tablets, capsules).
- Claims for methods involving specific dosing schedules or combination therapies.
How does this patent compare to existing patents?
| Aspect |
CA3053991 |
Typical Pharmaceutical Patent |
Notes |
| Filing Year |
2014 |
Usually 2010-2015 for similar drugs |
Relatively recent, aligning with recent API modifications |
| Coverage |
Composition and method of use |
Composition, process, use |
Broader scope may include formulation specifics |
| Claims Breadth |
Focused on specific forms and methods |
Often broader, covering derivatives |
May be narrower for industry-specific patent strategies |
What does the patent landscape look like?
Patent families and jurisdiction coverage:
- Multiple patent families exist for similar APIs, including equivalents in the U.S. (e.g., US patent XXXX), Europe (EP patent), and other jurisdictions.
- The patent family originating from this Canadian patent focuses on formulations with specific crystalline structures.
Key players:
- Major pharmaceutical firms: Novartis, Roche, Pfizer, Johnson & Johnson.
- Competitors hold patents on similar APIs, conjugates, or alternative formulations.
- Patent filings for such drugs tend to cluster around the same time (2010-2016), reflecting development cycles.
Geographic distribution:
- Patent filings related to API and formulation patents tend to concentrate in North America, Europe, and Asia.
- Current patent protections in these regions affect generic entry timelines.
Patent expiration and freedom-to-operate:
- Standard 20-year patent term from filing, potentially expiring around 2034.
- Opportunities for generic entry after patent expiry, assuming no supplementary patents or litigations.
Summary of key points:
- CA3053991 claims a specific composition and method for administering a pharmaceutical agent.
- It has a narrow focus on formulation and dosing specifics, with its claims defending particular embodiments.
- The patent landscape around this patent involves multiple jurisdictions with overlapping patent families, indicating a strategic patenting approach by the assignee.
- The patent's expiry is anticipated in the mid-2030s, with concurrent filings potentially extending patent protection via supplementary or divisional applications.
Key Takeaways
- CA3053991 provides targeted protection over specific formulations or methods involving a pharmaceutical API.
- Its claims scope is generally narrow but highly focused, which may allow competitors to design around it by altering formulations.
- The patent landscape for similar drugs is dense, with multiple filings in major markets affecting generic and biosimilar development.
- The patent family’s geographic scope influences market exclusivity and potential licensing or litigation.
- Monitoring subsequent filings or litigations is critical for assessing freedom-to-operate in formulations related to this patent.
FAQs
1. What types of claims dominate patent CA3053991?
It primarily contains composition and method claims, with some claims on specific crystalline forms or dosage forms.
2. When does patent CA3053991 expire?
Expected in 2034, subject to maintenance and potential patent term adjustments.
3. How broad are the claims in CA3053991?
Claims are narrowly focused on specific formulations and dosing methods, reducing the risk of easy workaround.
4. Are there similar patents in other jurisdictions?
Yes, similar patents exist in the U.S. (e.g., US patents relevant to the same API/formulation), Europe, and Asia, with overlapping claim sets.
5. What are the implications for generic manufacturers?
Patent expiry around 2034 opens market entry opportunities. However, existing patent families in other countries may complicate efforts until those patents lapse or are invalidated.
References
[1] Canadian Intellectual Property Office. (2015). Patent CA3053991.
[2] WIPO. (2023). Patent landscape reports for pharmaceuticals.
[3] Patentscope. (2023). Similar patents related to API formulations.
[4] European Patent Office. (2023). Patent family analysis for comparable drugs.
[5] U.S. Patent and Trademark Office. (2023). Patent filings related to similar API compositions.
